Politics

Poll: drug companies too powerful

Martin Shkreli, former CEO of Turing Pharmaceuticals, drew notoriety after his company raised the price of the lifesaving drug Daraprim from $13.50 per pill to $750 overnight. He is shown here in Washington during a 2016 House Oversight and Government Reform Committee hearing on the prescription drug market, where he invoked his right under the Fifth Amendment to not testify. He is flanked by Nancy Retzlaff, the chief commercial officer for Turing Pharmaceuticals. (PHOTO by Mark Wilson/Getty Images)
Martin Shkreli, former CEO of Turing Pharmaceuticals, drew notoriety after his company raised the price of the lifesaving drug Daraprim from $13.50 per pill to $750 overnight. He is shown here in Washington during a 2016 House Oversight and Government Reform Committee hearing on the prescription drug market, where he invoked his right under the Fifth Amendment to not testify. He is flanked by Nancy Retzlaff, the chief commercial officer for Turing Pharmaceuticals. (PHOTO by Mark Wilson/Getty Images)
March 28, 2018

Americans are more concerned about the influence of pharmaceutical companies in Washington than they are about Wall Street, labor unions or the National Rifle Association, according to a new poll.

Soaring drug prices are in the news. In Georgia the Medicaid budget alone put more than $700 million toward pharmacy services. And that doesn't touch what Georgians with their own insurance or no insurance are doling out.

In the poll, 72 percent of respondents said the pharmaceutical industry had too much influence in Washington, second only to “large businesses” at 76 percent. Next down was Wall Street at 69 percent. Many other medical businesses mentioned in the poll didn’t come close.

Some groups that provoke strong reactions were included, such as labor unions, typically seen as liberal, and the NRA, typically seen as conservative. They registered just 28 percent and 52 percent, respectively, of respondents saying they had too much influence.

The Kaiser Family Foundation, a nonprofit research group, runs the tracking poll periodically, and it conducted the latest one earlier this month.

There is no shortage of ammunition for critics of the pharmaceutical industry's influence. The government isn't allowed to negotiate drug prices for Medicare, for example, and the new secretary of health and human services, Alex Azar, is a former pharmaceutical executive.

However, President Donald Trump said in his State of the Union address that “one of (his) greatest priorities is to reduce the price of prescription drugs.”

Stay on top of what’s happening in Georgia government and politics at PoliticallyGeorgia.com.

About the Author

Ariel Hart is a reporter on health care issues. She works on the AJC’s health team and has reported on subjects including the Voting Rights Act and transportation.

More Stories